[Efficacy of 40-O-(2-hydroxyethyl)-rapamycin in preventing chronic renal allograft rejection in rats].
OBJECTIVE
To study the efficacy of 40-O-(2-hydroxyethyl)-rapamycin (SDZ RAD) in preventing chronic renal allograft rejention in rats.


METHODS
The rat model of chronic renal allograft rejection was made with micro-surgery. The recipients were divided into two groups. The recipients in the study group were treated with SDZ RAD at a dose of 0.5 mg x kg(-1) x d(-1) by means of gavage and the controls with vehicle.


RESULTS
After 24 weeks of treatment, proteinuria, glomerular sclerosis, vascular intimal thickening and the infiltration of monocytesmacrophages and lymphocytes in the study group were decreased, in consistence with the reduced expression of ICAM-1, VCAM-1, TGF-beta(1) and PDGF-AA mRNA.


CONCLUSIONS
It is suggested that SDZ RAD can prevent chronic renal allograft rejection and the reduced expression of above adhesion molecules and growth factors may be involved in the mechanism.
Zou
H
H
Institute of Transplantation, Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University of Medical Sciences, Guangzhou 510120.
Bai
J
J
Lai
D
D
D000818:Animals; D000068338:Everolimus; D006084:Graft Rejection / Q000517:prevention & control*; D007150:Immunohistochemistry; D007166:Immunosuppressive Agents / Q000627:therapeutic use*; D018799:Intercellular Adhesion Molecule-1 / Q000032:analysis; D016030:Kidney Transplantation; D008297:Male; D010982:Platelet-Derived Growth Factor / Q000235:genetics; D012333:RNA, Messenger / Q000032:analysis; D051381:Rats; D011916:Rats, Inbred F344; D011917:Rats, Inbred Lew; D020123:Sirolimus / Q000031:analogs & derivatives / Q000627:therapeutic use*; D014184:Transplantation, Homologous; D019010:Vascular Cell Adhesion Molecule-1 / Q000032:analysis
D007166:Immunosuppressive Agents; D010982:Platelet-Derived Growth Factor; D012333:RNA, Messenger; D019010:Vascular Cell Adhesion Molecule-1; D018799:Intercellular Adhesion Molecule-1; D000068338:Everolimus; D020123:Sirolimus